ST. LOUIS, July 22 MO-SIAL-Q2-Earnings
ST. LOUIS, July 22 /PRNewswire-FirstCall/ --
HIGHLIGHTS:
2008 Results (all percentage comparisons are to comparable periods in
2007):
-- Q2 2008 Sales Set New Quarterly Record: Q2 2008 sales reached another
new quarterly high of $580.7 million, an increase of 14.4%. All four
business units reported double-digit growth for the third successive
quarter. Organic sales growth of 7.1% confirmed earlier expectations
regarding the roughly one percentage point impact of the Easter
holidays from Q1 to Q2 sales growth. Currency added another
7.3 percentage points to growth. Quarterly comparisons and a
reconciliation of reported to adjusted sales growth can be found in the
Supplemental Financial Information, Sales Growth by Business Unit
table.
-- Operating And Pretax Margins Continued Strong as Pretax Income Growth
Exceeds Sales Growth: Q2 2008 operating and pretax income margins were
23.1% and 22.6%, respectively, an improvement over the Q2 2007 level.
Pretax income increased 19.4% in Q2 2008.
-- Double-Digit EPS Growth Despite Higher Tax Rates: Q2 2008 diluted EPS
increased 16.7% to $.70, including $.08 from favorable currency rates
offset by $.03 from a higher tax rate. A previously communicated
reduction in tax benefits resulted in an effective tax rate of 30.8% in
Q2 2008 compared to 27.5% for Q2 2007. An explanation of the tax rate
difference and a reconciliation of currency adjusted proforma to
reported diluted EPS for the quarter can be found on in the Outlook
section and the Supplemental Financial Information, Reconciliation of
Proforma to Reported Net Income table.
-- Significant Increase In Cash Flow From Operations: Cash flow from
operations for the first six months of 2008 improved by 36.8% to
$222.0 million.
Outlook:
-- Sales for full year 2008 are expected to meet the Company's 7% organic
growth goal. Currency benefits could add another 6% to growth if
currency exchange rates remain at June 30, 2008 levels.
-- Currency, lower interest rates, our supply chain initiative and other
process improvements are expected to enhance pretax profit margins for
full year 2008 from the 21.5% pretax margin achieved in full year 2007.
-- Management has increased its estimate for full year 2008 diluted EPS by
$.05 to a new range of $2.62 to $2.72, an increase of 12.0% to 16.2%
over 2007, based on these sales expectations, both higher than expected
margins in Q2 2008 and those forecast for the remaining quarters of
2008, currency rates remaining at June 30, 2008 levels, an effective
tax rate ranging from 30% to 32% and other factors.
CEO's STATEMENT:
Commenting on second quarter performance and expectations for the full
year of 2008, President and CEO Jai Nagarkatti said: "We are pleased with our
strong second quarter performance as we continue to pursue and achieve above
market growth from the five key initiatives driving our sales gains and
returns. Our second quarter sales of $580.7 million, which included the best
sales month in the Company's history in June, represent another new quarterly
high, exceeding the record established just one quarter ago. And we were able
to grow EPS faster than sales and improve operating margins as ongoing process
improvement activities, lower interest costs and benefits from our supply
chain initiative combined to more than offset other cost increases and the
impact of a higher effective tax rate."
Nagarkatti continued, "We're in the final year of our 2006-2008 strategic
plan, and are in the process of identifying the activities that are expected
to drive growth at above market rates for the next three years. Results from
our current initiatives are meeting, and in some cases, exceeding
expectations. Second quarter achievements for our five key growth initiatives
included:
-- Improved growth for all three of our Research-based business units and
a record sales amount for SAFC, our Fine Chemicals unit, as we
continued to enhance our customer centric activities. Research
Essentials and Research Specialties achieved sales growth in excess of
long-term growth targets, and Research Biotech exceeded current year
growth expectations, all after factoring out a modest benefit in the
second quarter from holiday timing differences between 2008 and 2007.
And SAFC had another increase in its booked orders for future delivery
to again achieve a new record level;
-- Increasing reported and adjusted sales in CAPLA (Canada, Asia Pacific
and Latin America) markets by 19.3% and 11.3%, respectively, in Q2
2008, with a Q2 2008 revenue contribution from these markets at 20% of
sales, a one percentage point improvement over results for the
comparable quarter of 2007 and consistent with level achieved for all
of 2007. Reported quarterly sales growth in our primary focus markets
of India, Brazil and China ranged from 10% to 45% as we continued to
increase our presence in each of these markets through new sales
activities, completed and planned increases in production capacity, and
inventory stocking initiatives;
-- Increasing web-based sales through our award winning website by 21.9%.
Overall web-based sales improved to 42% of worldwide Q2 2008
Research-based sales as e-commerce sales to international (Europe and
CAPLA) customers rebounded in Q2 to increase by 32.4%. E-commerce sales
to U.S. Research customers were 52% of total U.S. Research sales, a one
percentage point improvement from the level achieved in Q1 2008;
-- Continuing our commitment to process improvement savings, supporting an
expectation of achieving at least $15 million in pretax benefits for
2008 by delivering $3.5 million of benefits during the second quarter
of 2008, bringing the year-to-date benefit to $8.3 million. If the
adverse impact of higher currency rates on operating costs outside the
U.S. is excluded, the year-to-date results were even more robust at
roughly $12 million. And our supply chain project is well under way
and achieving desired results with a modest contribution to second
quarter pretax profits as we seek to take process improvement to a
higher level and boost both EPS growth and margins through 2012; and
-- Adding new capabilities in our Research Biotech business unit by
expanding our role with The Research Consortium and entering new
collaborations with the University of California-San Francisco,
Metahelix Life Sciences and Sunset Molecular Discovery to increase
product offerings and available information in the areas of monoclonal
antibodies, plant bioscience products and bioactive molecules."
Nagarkatti concluded, "We expect this momentum to carry through the final
quarters of 2008, enabling us to meet our 7% organic sales growth goal,
generate margin expansion and deliver our increased forecast for diluted EPS
of $2.62 to $2.72 for the full year."
SALES RESULTS (all percentage comparisons are to comparable periods in
2007):
A reconciliation of reported and adjusted sales growth and quarterly sales
by business unit can be found in tabular form in the Supplemental Financial
Information section. The quarterly sales data by business unit for 2007
presented in this section includes reclassifications to conform to 2008
classifications that reflect transfers of certain products between business
units to better align the selling effort for those products with their primary
customers.
Reported sales increased 14.4% for the second quarter of 2008 to a new
quarterly record of $580.7 million. Second quarter organic sales growth,
excluding currency benefits, was 7.1%. Overall organic sales growth for the
three Research-based business units (Research Specialties, Research Essentials
and Research Biotech) improved to 8.1% in Q2 2008 from 5.7% in Q1 2008,
reflecting both improved demand for core Research products and the natural
reversal of the dampening impact of the timing of the Easter holiday on Q1
growth that had been predicted. Other highlights for our four business units
included:
Research Specialties (Reported growth- Q2: 16.8%, YTD: 15.3%; Organic
growth- Q2: 8.7%, YTD: 7.2%): This unit continued its exceptional performance
in Q2 2008 with run rate growth (adjusting for the estimated benefit from the
holiday timing on organic growth) exceeding its 6% long-term organic growth
target for each of the last eight quarters. Improved demand from the academic
sector in both the U.S. and Europe continued. Growth was also helped by a
brand consolidation initiative that enabled us to streamline our product
offering to make products easier to find and improve service, and from
improved customer profiles that enabled us to provide more timely and relevant
product information to our customers.
Research Essentials (Reported growth- Q2: 13.5%, YTD: 12.1%; Organic
growth- Q2: 5.6%, YTD: 4.4%): Q2 2008 organic sales growth continued the
pattern of exceeding expectations (after reflecting the estimated holiday
impact between Q1 and Q2 2008) in each of the last five quarters. Strong sales
gains of research-based cell culture and lab essentials products were helped
by continued improvement in sales to academic accounts in the U.S. and Europe.
Research Biotech (Reported growth- Q2: 17.6%, YTD: 17.1%; Organic
growth- Q2: 9.8%, YTD: 9.4%): Continued stronger spending by academic
customers worldwide enhanced sales growth for molecular biology and cell
signaling products. Our short-term actions to add innovative new products
across the drug discovery workflow through internal efforts, new
collaborations and partnerships, as well as programs to market our products
more effectively continued to benefit sales growth over the last four
quarters. Pricing and demand for synthetic DNA products remained consistent
with that experienced in Q1 2008, reversing the adverse impact on overall
sales growth that DNA products had during 2007.
SAFC (Reported growth- Q2: 10.7%, YTD: 14.2%; Organic growth- Q2: 4.7%,
YTD: 6.4%): Q2 2008 sales of $170.4 million marked the third successive
quarter for achieving a new quarterly sales record. Continued strong growth
in Hitech products matched with steady growth for Supply Solutions products
was partially offset by moderating demand for industrial cell culture and
custom pharma products and the traditionally variable quarterly performance
from these product groups. Booked orders for future delivery at June 30, 2008
increased by another 4% from March 31, 2008 levels to another all time high.
INCOME ANALYSIS:
A reconciliation of currency adjusted proforma to reported net income and
diluted earnings per share can be found in tabular form in the Supplemental
Financial Information section.
Reported diluted EPS for 2008's second quarter of $.70, which includes an
$.08 benefit from currency exchange rates, partially offset by approximately
$.03 due to a higher effective tax rate, increased 16.7% over the $.60
reported for 2007's second quarter.
Gross profit, S,G&A expenses and operating and pretax income, all
expressed as a percentage of sales, and the effective tax rate (income tax
expense expressed as a percentage of pretax income), for the second quarters
and first six months of 2008 and 2007, were as follows:
Second Quarter Year-To-Date
2008 2007 2008 2007
Gross profit 50.8% 51.3% 51.0% 51.3%
S,G&A expenses 24.9% 25.7% 25.4% 25.6%
Operating income 23.1% 22.8% 22.9% 22.8%
Pretax income 22.6% 21.7% 22.2% 21.7%
Effective tax rate 30.8% 27.5% 31.4% 28.9%
Operating and pretax income margins for Q2 2008 improved over those
achieved in Q2 2007. The lower gross profit margins in Q2 2008 compared to Q2
2007 resulted largely from higher manufacturing and distribution expenses,
including increases in freight and utility costs, partially offset by process
improvement benefits and the Company's supply chain initiative. The decline
in the S,G&A expense percentage reflects the relatively fixed nature of these
costs spread over higher sales levels during Q2 2008, with modest benefits
from the Company's process improvement activities and lower legal expenses.
Interest expense for Q2 2008 was $2.6 million below the Q2 2007 level due to
lower interest rates partially offset by increased borrowing to support a
higher level of share repurchases during the quarter.
The higher effective tax rate for Q2 2008 compared to the same period in
2007 reflects a higher level of net international and state and local taxes
and the absence of U.S. R&D tax credits in 2008, partially offset by an
increase in the U.S. manufacturing deduction.
OUTLOOK:
2008 Expectations: Ongoing benefits from the programs in place to support
our five key strategic initiatives are expected to enable the Company to meet
its 7% long-term organic growth goal for 2008. Currency benefits could add 6%
to this organic growth if currency exchange rates remain at June 30, 2008
levels. The carryover benefit from the February 2007 Epichem acquisition,
which has been reflected in only Q1 2008 results, will make an additional
modest contribution to full year 2008 growth.
The net transfer of products between our business units (noted in the
Sales Results section) to better align the selling effort for these products
with their primary customers has not changed our growth goals for these
business units. Research Essentials is expected to deliver sales growth of 4%
to 5%, equaling or exceeding its long-term organic sales growth goal of 4%.
This unit plans to continue to take advantage of opportunities in CAPLA
markets through increased service levels. Research Specialties plans to
extend the activities that have driven its growth at above target levels over
the past eight quarters, with an expectation of organic sales growth
consistent with its previously communicated sales growth of 7% to 8% for the
year, remaining well ahead of its 6% long-term goal. With a strong first half
in 2008 and better than expected results from new product offerings and
marketing programs, Research Biotech is expected to continue its positive
momentum and deliver improved organic growth of at least 8% for 2008.
SAFC achieved record sales levels in each of the last three quarters and
reached a new high in booked orders for future delivery at June 30, 2008, but
recent economic and industry conditions and discussions with customers have
led us to moderate growth expectations for the full year from 8% to 9% to a
new range of 5% to 6%, reflecting the likely impact of reduced spending by
select customers for our custom pharmaceutical products. A carryover benefit
in Q1 2008 from the February 2007 acquisition of Epichem, an innovator in
developing and supplying high performance semiconductor materials, is expected
to add modestly to full year organic growth.
Ongoing efforts to identify and pursue desirable acquisition candidates or
technology access arrangements may further enhance growth in 2008 as we
continue to seek to add additional annual revenue through the acquisition of
strategically important products, services, platform technologies, businesses
and facilities.
Our forecast for diluted earnings per share for all of 2008 is increased
by $.05 to a new range of $2.62 to $2.72, a 12.0% to 16.2% increase over
2007's $2.34, based on our 2008 year-to-date results, the sales expectations
described above, currency rates remaining at June 30, 2008 levels, the
expected pretax income margin and tax rate described below and other
expectations for our business. Pretax income margins for the full year are
expected to improve from the 21.5% achieved in 2007 as the result of favorable
currency rates, lower interest rates, modest contributions from the Company's
supply chain initiative and other margin improvement initiatives. Anticipated
input cost increases are expected to be offset by higher selling price
increases, with ongoing monitoring of these costs to achieve desired margins.
A higher forecasted effective tax rate in the range of 30% to 32% of pretax
income for all of 2008 will likely partially offset pretax margin
improvements. The effective tax rate for 2008 is expected to increase due to
a higher net international tax level versus 2007 and the expiration of the
U.S. R&D tax credit. Reinstatement of the U.S. R&D tax credit by the U.S.
Congress and/or other known tax reduction activities could drive the tax rate
for 2008 from our higher year-to-date level to the mid-point or lower end of
the forecasted range. Variations to our forecast tax rate and forecast
diluted EPS for 2008 are also possible due in part to changes in the status of
tax uncertainties pursuant to FASB Interpretation No. 48, "Accounting for
Uncertainty in Income Taxes." Additional modest share repurchase activity may
also benefit EPS growth.
Supply Chain Initiative: The Company's previously announced supply chain
project is an ambitious five-year project that is expected to improve service
and enable us to expand margins through eight separate but complementary
supply chain initiatives focused on improving how we procure goods and
services, manage inventory and execute other supply chain activities that are
key to our customer centric approach. While the project commenced in 2007 and
management expects it to be mildly accretive to profitability in 2008,
management does not expect significant annual pretax income benefits to result
until 2009. Estimated annual pretax benefits of $10 to $15 million, as early
as 2009, are expected to increase in roughly ratable amounts to between $35
and $45 million annually by 2012. Based on current shares outstanding, this
could increase diluted earnings per share by $.05 to $.08 in 2009, increasing
to $.19 to $.24 by 2012, and improve pretax and operating margins by as much
as 150 basis points when the full benefits of the project are realized. These
benefits are above and beyond our current expectations to continue to generate
$15 million in annual pretax savings from process improvements, with the
majority of these $15 million in savings expected to be reinvested to support
achieving revenue growth targets just as they have been historically.
OTHER INFORMATION:
Return On Equity: Our ROE at June 30, 2008 was 21.3%, continuing to
exceed our 20% goal.
Share Repurchase: Another 3.1 million shares were acquired during Q2 2008
at an average price of $58.51 per share. Since beginning the program in late
1999, 88.0 million shares have been acquired at an average purchase price of
$22.15 per share. There were 126.0 million shares outstanding at June 30,
2008. The Company expects to repurchase 2.0 million more authorized shares,
but the timing and number of shares purchased, if any, will depend upon market
conditions and other factors.
Cash Flow, Working Capital and Debt: Cash flow from operations for the
first six months of 2008 compared to 2007 increased by $59.7 million or 36.8%
to $222.0 million as deferred income taxes and the growth in inventory
investment declined from 2007 levels. This cash flow, together with a $51.3
million increase in debt and other non-operating cash sources, enabled us to
fund $230.5 million for share repurchases, pay $42.2 million for property and
equipment additions and return $33.2 million to shareholders through a 13%
increase in the quarterly dividend. We expect to continue to have adequate
cash and borrowing capacity to fund all anticipated requirements for
operations and acquisitions over the remainder of 2008.
Short-term borrowings were $394.0 million at a weighted average interest
rate of 2.4% and long-term debt was $200.1 million at a weighted average
interest rate of 6.4% at June 30, 2008. Our debt to capital ratio at June 30,
2008 was 26.9%.
Accounts receivable days sales outstanding at June 30, 2008 were 51 days,
consistent with the level at June 30, 2007, but reduced from the 53 days
outstanding at March 31, 2008 that had reflected a temporary increase related
to the timing of customer payments. Inventory months on hand were 7.2 months
at June 30, 2008 compared to a 7.3 month level at year-end 2007.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High
Technology company. Our biochemical and organic chemical products and kits are
used in scientific and genomic research, biotechnology, pharmaceutical
development, the diagnosis of disease and as key components in pharmaceutical
and other high technology manufacturing. We have customers in life science
companies, university and government institutions, hospitals and in industry.
Over one million scientists and technologists use our products. Sigma-Aldrich
operates in 36 countries and has 8,000 employees providing excellent service
worldwide. We are committed to accelerating our Customers' success through
leadership in Life Science, High Technology and Service. For more information
about Sigma-Aldrich, please visit our award winning web site at
http://www.sigma-aldrich.com.
Non-GAAP Financial Measures: The Company uses certain non-GAAP financial
measures to supplement its GAAP disclosures. The Company does not, and does
not suggest investors should, consider such non-GAAP financial measures in
isolation from, or as a substitute for, GAAP financial information. These
non-GAAP measures may not be consistent with the presentation by similar
companies in the Company's industry. Whenever the Company uses such non-GAAP
measures, it provides a reconciliation of such measures to the most closely
applicable GAAP measure.
With over 60% of sales denominated in currencies other than the U.S.
dollar, management uses currency adjusted growth, and believes it is useful to
investors, to judge the Company's controllable, local currency performance.
Organic sales growth data presented in this release is proforma data and
excludes currency, and where indicated, acquisition impacts. While we are able
to report currency impacts after the fact, we are unable to estimate changes
that may occur later in 2008 to applicable exchange rates and are thus unable
to reconcile the projected non-GAAP, currency adjusted internal growth rates
to reported GAAP growth rates for the year 2008. Any significant changes in
currency exchange rates would likely have a significant impact on our reported
growth rates due to the volume of our sales denominated in foreign currencies.
Management also reports both GAAP and adjusted sales, income and process
improvement savings amounts and comparisons to reflect what it believes is
ongoing and/or comparable operating results excluding currency impacts and the
sales benefit from acquisitions. Management excludes these other items in
judging its historical performance and in assessing its expected future
performance and believes this non-GAAP information is useful to investors as
well.
Cautionary Statement: This release contains forward-looking statements
relating to future performance, goals, strategic actions and initiatives and
similar intentions and beliefs, including the "Highlights", "CEO's Statement",
"Sales Results", "Income Analysis", "Outlook", and "Other Information-Share
Repurchase" sections contained above and other statements regarding the
Company's expectations, goals, beliefs, intentions and the like regarding
future sales, earnings, share repurchases, acquisitions and other matters.
These statements involve assumptions regarding Company operations, investments
and acquisitions and conditions in the markets the Company serves. Although
the Company believes its expectations are based on reasonable assumptions,
such statements are subject to risks and uncertainties, including, among
others, certain economic, political and technological factors. Actual results
could differ materially from those stated or implied in this news release, due
to, but not limited to, such factors as (1) changes in pricing and the
competitive environment, (2) fluctuations in foreign currency exchange rates,
(3) dependence on uninterrupted manufacturing operations, (4) changes in the
regulatory environment in which the Company operates, (5) changes in worldwide
tax rates or tax benefits from domestic and international operations,
including the matters described in Note 4- Uncertainty in Income Taxes- to the
Consolidated Financial Statements in the Company's Form 10-Q report for the
quarter ended March 31, 2008, (6) exposure to litigation, including product
liability claims, (7) changes in research funding and the success of research
and development activities, (8) the ability to maintain adequate quality
standards, (9) reliance on third party package delivery services, (10) the
impact of acquisitions and success in integrating and obtaining projected
results from the acquisitions, (11) other changes in the business environment
in which the Company operates, and (12) the outcome of the matters described
in Note 13 -- Contingent Liabilities and Commitments -- to the Consolidated
Financial Statements in the Company's Form 10-Q report for the quarter ended
March 31, 2008. A further discussion of the Company's risk factors can be
found in Item 1A of the Company's Form 10-K report for the year ended December
31, 2007. The Company does not undertake any obligation to update these
forward-looking statements.
SIGMA-ALDRICH CORPORATION
Consolidated Statements of Income (Unaudited)
(in millions except per share amounts)
Three Months Six Months
Ended June 30, Ended June 30,
2008 2007 2008 2007
Net sales $580.7 $507.5 $1,150.3 $1,003.4
Cost of products sold285.8 247.0 563.2 488.5
Gross profit 294.9 260.5 587.1 514.9
Selling, general and administrative
expenses144.5 130.3 292.2 257.2
Research and development expenses 16.0 14.5 31.9 28.6
Interest, net 3.25.87.4 11.7
Income before income taxes 131.2 109.9 255.6 217.4
Provision for income taxes40.4 30.2 80.3 62.8
Net income $90.8 $79.7 $175.3 $154.6
Net income per share - Basic $0.71 $0.61 $1.37 $1.18
Net income per share - Diluted $0.70 $0.60 $1.34 $1.16
Weighted average number of shares
outstanding - Basic 127.5 130.8 128.3 131.3
Weighted average number of shares
outstanding - Diluted 130.2 133.2 131.0 133.6
SIGMA-ALDRICH CORPORATION
Consolidated Balance Sheets
(in millions)
(Unaudited)
June 30, December 31,
2008 2007
Assets
Current assets:
Cash and cash equivalents $240.3$237.6
Accounts receivable, net 328.8 276.3
Inventories 687.9 653.6
Deferred taxes72.9 57.7
Other current assets 55.2 57.3
Total current assets 1,385.1 1,282.5
Property, plant and equipment, net 689.6 681.5
Goodwill, net 425.6 420.3
Intangibles, net 131.4 136.9
Other assets 105.0 107.9
Total assets$2,736.7 $2,629.1
Liabilities and Stockholders' Equity
Current liabilities:
Notes payable and current maturities of
long-term debt $394.0$331.3
Accounts payable 128.4 131.0
Accrued payroll and payroll taxes 56.6 55.0
Accrued income taxes 82.8 47.1
Other accrued expenses78.8 70.6
Total current liabilities 740.6 635.0
Long-term debt 200.1 207.0
Deferred post-retirement benefits 37.0 36.9
Deferred taxes 45.0 42.3
Other liabilities 100.7 91.3
Total liabilities1,123.4 1,012.5
Stockholders' equity:
Common stock 201.8 201.8
Capital in excess of par value 123.9 109.7
Common stock in treasury (1,751.8) (1,534.1)
Retained earnings 2,820.6 2,679.3
Accumulated other comprehensive income 218.8 159.9
Total stockholders' equity 1,613.3 1,616.6
Total liabilities and stockholders' equity $2,736.7 $2,629.1
SIGMA-ALDRICH CORPORATION
Consolidated Statements of Cash Flows (Unaudited)
(in millions)
Six Months
Ended June 30,
2008 2007
Cash flows from operating activities:
Net income$175.3$154.6
Adjustments to reconcile net income to net
cash provided by operating activities:
Depreciation and amortization 51.0 48.4
Deferred income taxes(10.8)(36.8)
Stock-based compensation expense 10.8 10.3
Other 0.8 5.8
Changes in assets and liabilities:
Increase in accounts receivable (40.3)(37.2)
Increase in inventories (8.6)(20.4)
Increase in accrued income taxes 29.9 24.7
Other 13.9 12.9
Net cash provided by operating activities 222.0 162.3
Cash flows from investing activities:
Property, plant and equipment additions(42.2)(36.4)
Proceeds from sale of property, plant and
equipment 0.2 1.0
Acquisitions of businesses, net of cash
acquired- (69.1)
Other, net 1.6 7.5
Net cash used in investing activities (40.4)(97.0)
Cash flows from financing activities:
Net issuance of short-term debt141.3 66.2
Repayment of long-term debt(90.0)(19.6)
Payment of dividends (33.2)(30.1)
Treasury stock purchases (230.5)(84.5)
Exercise of stock options 13.9 13.6
Excess tax benefits from stock-based payments4.8 2.9
Net cash used in financing activities (193.7)(51.5)
Effect of exchange rate changes on cash 14.8 2.5
Net change in cash and cash equivalents2.7 16.3
Cash and cash equivalents at January 1 237.6 173.8
Cash and cash equivalents at June 30$240.3$190.1
SIGMA-ALDRICH CORPORATION
Supplemental Financial Information - (Unaudited)
Sales Growth by Business Unit
Three Months
Ended June 30, 2008
Currency Adjusted
Reported Benefit Acquisition (Organic)
Research Essentials13.5% 7.9% - % 5.6%
Research Specialties 16.8% 8.1% - % 8.7%
Research Biotech 17.6% 7.8% - % 9.8%
SAFC 10.7% 6.0% - % 4.7%
Total 14.4% 7.3% - % 7.1%
Six Months
Ended June 30, 2008
Currency Adjusted
Reported Benefit Acquisition (Organic)
Research Essentials12.1% 7.7% - % 4.4%
Research Specialties 15.3% 8.1% - % 7.2%
Research Biotech 17.1% 7.7% - % 9.4%
SAFC 14.2% 6.4% 1.4% 6.4%
Total 14.6% 7.5% 0.4% 6.7%
Business Unit Sales
(in millions)
First SecondThird Fourth
Quarter Quarter QuarterQuarterTotal
2007 2007 2007 2007 2007
Research Essentials $99.4$96.4 $95.6 $99.3$390.7
Research
Specialties 187.3183.7 184.6 197.9 753.5
Research Biotech 76.0 73.5 72.9 79.6 302.0
SAFC 133.2153.9 150.1 155.3 592.5
Total Customer
Sales $495.9 $507.5$503.2$532.1 $2,038.7
First Second
Quarter QuarterYTD
2008 2008 2008
Research Essentials $110.1 $109.4$219.5
Research
Specialties 213.3214.5 427.8
Research Biotech 88.7 86.4 175.1
SAFC 157.5170.4 327.9
Total Customer
Sales $569.6 $580.7 $1,150.3
NOTE: 2007 Business Unit sales data reflects reclassifications to
conform to the 2008 classification that reflects transfers of
certain products between business units to better align the
selling effort for those products with their primary customers.
SIGMA-ALDRICH CORPORATION
Supplemental Financial Information - (Unaudited)
Reconciliation of Proforma to Reported Net Income
Net IncomeDiluted Earnings
(in millions) Per Share
Three Months Ended Three Months Ended
June 30, June 30,
2008200720082007
Proforma net income before currency
benefit $80.2 $79.7 $0.62 $0.60
Currency benefit 10.6 - 0.08 -
Total reported net income$90.8 $79.7 $0.70 $0.60
Net IncomeDiluted Earnings
(in millions) Per Share
Six Months Ended Six Months Ended
June 30, June 30,
2008200720082007
Proforma net income before currency
benefit$151.3 $154.6 $1.16 $1.16
Currency benefit 24.0 - 0.18 -
Total reported net income $175.3 $154.6 $1.34 $1.16
SOURCE Sigma-Aldrich
